Clinical Trial

An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis

Study acronym: ALS
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 16, 2024 (before its estimated April 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label, single-arm investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SNUG01 in patients with Amyotrophic Lateral Sclerosis (ALS).
Trial Details
NCT Number NCT06645197
Lead Sponsor Peking University Third Hospital
Collaborators: SineuGene Therapeutics Co., Ltd.
Conditions Amyotrophic Lateral Sclerosis (ALS)
Enrollment 7 participants
Start Date 2024-10-16
Primary Completion 2025-04-15 (estimated)
Study Completion 2029-10-15 (estimated)
Updated on ClinicalTrials.gov 2024-10-16